June 1, 2019
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x.
R. Wuerstlein, R. Kates, O. Gluz, E.M. Grischke, C. Schem, M. Thill, S. Hasmueller, A. Köhler, B. Otremba, F. Griesinger, C. Schindlbeck, A. Trojan, F. Otto, M. Knauer, R. Pusch, N. Harbeck, WSG-PRIMe investigators in Germany, Austria, Switzerland
MammaPrint and BluePrint test results strongly impacted physicians’ therapy decisions in luminal EBC with up to three involved lymph nodes. The high adherence to genetically determined risk assessment represents a key prerequisite for achieving a personalized cost-effective approach to disease management of early breast cancer.